Nanomedicines from the patient perspective - 30 years after PEGylated liposomal doxorubicin.
Saved in:
| Title: | Nanomedicines from the patient perspective - 30 years after PEGylated liposomal doxorubicin. |
|---|---|
| Authors: | Wang L; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada. Electronic address: lucille.wang@mail.utoronto.ca., Sehdev S; Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada., Nadeem A; Patient Advocacy Group, Ovarian Cancer Canada, Toronto, ON M2P 2A9, Canada., Allen C; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada; Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, ON M5S 3E5, Canada. Electronic address: cj.allen@utoronto.ca. |
| Source: | Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2026 May 20; Vol. 396, pp. 115038. Date of Electronic Publication: 2026 May 20. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4995 (Electronic) Linking ISSN: 01683659 NLM ISO Abbreviation: J Control Release Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1873-4995 |
|---|---|
| DOI: | 10.1016/j.jconrel.2026.115038 |
